GLENMARK PHARMACEUTICALS vs ZYDUS LIFESCIENCES LTD

A side-by-side comparison of GLENMARK PHARMACEUTICALS (GLENMARK) and ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, ZYDUS LIFESCIENCES LTD leads GLENMARK vs ZYDUSLIFE on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability22
  • Growth11
  • Size & financial health13
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

ZYDUSLIFE takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

50.87
P/E ratio
23.20
5.90
P/B ratio
4.09
0.20%
Dividend yield
0.08%
₹48.26
EPS
₹50.09

Profitability

Even

How efficiently each company turns capital and sales into profit. Higher is better.

30.50%
Return on equity
21.20%
40.00%
Return on capital
21.00%
27.00%
EBITDA margin
31.00%
8.02%
Net margin
18.87%

Growth

Even

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

13.61%
Revenue CAGR (3Y)
16.35%
53.44%
Profit CAGR (3Y)
34.80%

Size & financial health

ZYDUSLIFE takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹69,740 Cr
Market cap
₹1.18L Cr
₹16,983 Cr
Revenue
₹27,148 Cr
₹1,362 Cr
Net profit
₹5,124 Cr
0.00
Debt / equity
0.31
GLENMARK PHARMACEUTICALS
  • + ["Company has reduced debt.", "Company is almost debt free.", "Company has delivered good profit growth of 19.4% CAGR over last 5 years"]
  • ["The company has delivered a poor sales growth of 9.19% over past five years.", "Company has a low return on equity of -3.28% over last 3 years.", "Debtor days have increased from 85.2 to 107 days.", "Working capital days have increased from 41.2 days to 80.5 days"]
ZYDUS LIFESCIENCES LTD
  • + ["Company has delivered good profit growth of 18.8% CAGR over last 5 years"]
GLENMARK PHARMACEUTICALS full analysis ZYDUS LIFESCIENCES LTD full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

GLENMARK vs ZYDUSLIFE: Share Price, Valuation & Which to Buy | DocStoX